Bristol-Myers Squibb appoints new UK general manager
pharmafile | December 13, 2010 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Amadou Diarra, BMS, Bristol-Myers Squibb, appointment, recruitment, sales and marketing
Bristol-Myers Squibb has appointed Amadou Diarra as general manager of its UK company, where he will be in charge of 440 staff working across three sites.
Amadou, who will be based in Uxbridge and report to Europe president Ron Cooper, joins from BMS’ French operations where he served as VP of market access for Europe.
Commenting on his new role Amadou said: “We have specific access challenges here, and the UK continues to be a strong predictor of future trends for the rest of Europe so I am looking forward to leading cross‐functional teams that deliver robust access strategies and a continuing strong business performance for the UK.”
During a 20-year career with BMS Amadou has held a number of general manager roles in markets such as Indonesia, Turkey, Ireland and the Nordic region.
In a statement BMS said: “In all of these previous roles, Amadou has been an active member of the national industry association and has participated in industry initiatives to deliver on the access agenda.”
Prior to becoming a general manager, Amadou was based in Bristol‐Myers Squibb’s global HQ in Princeton, New Jersey, where he led the firm’s philanthropic programme, Secure The Future. This public‐private partnership focused on care and support for women and children infected or affected by HIV in Sub-Saharan Africa.
Amadou is a French national, originating from Mali and Niger, but grew up in Senegal and Ivory Coast. He later graduated as a pharmacist and gained his MBA back in France.
Dominic Tyer
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
